LAG-3 antagonists for cancer treatment: an updated patent review (2020–2025)
The trend shows that monospecific antibodies against LAG-3 continue to be the main antagonists, followed by multispecific t, treatment methods using known LAG-3 antagonists, LAG-3 binding peptides, and LAG-3 binding small molecules. The monospecific antibodies encelimab, miptenalimab, and the bispecific antibodies tobemstomig, IBI323, ABL501, fanastomig, and FS118 are added, during this period, to the potential drugs targeting LAG-3.
Authors
- Patricia Martínez‐Morales (ORCID: https://orcid.org/0000-0003-1615-2570)
- Dublán-García Octavio
- Donaciano Flores-Robles
- Tayde Guerrero-González (ORCID: https://orcid.org/0000-0003-3957-7918)
- R. Ramos-Enríquez
- Francisco Marroquín-Gutiérrez (ORCID: https://orcid.org/0000-0002-0920-9762)
- Genaro Vargas-Hernández
- Maricruz Anaya-Ruiz
- Blanca Jaramillo-Loranca
- Martín Pérez-Santos
- Gerardo Landeta
Institutions
- Mexican Social Security Institute (MX)
- Universidad Autónoma del Estado de México (MX)
- Universidad Autónoma de Guerrero (MX)
- Universidad de Sonora (MX)
- Universidad Politécnica de Pachuca (MX)
- Benemérita Universidad Autónoma de Puebla (MX)
- Institute for Social Security and Services for State Workers (MX)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1080/13543776.2026.2614492
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00